In its latest financial results, Cambridge, Mass.-based Vericel (NSDQ:VCEL) saw sales climb 60% for its permanent skin-replacement product, Epicel, designed for patients with severe burns. Sales for its autologous cellular scaffold, Maci, were up 20% following its launch to the commercial market. Vericel’s growing product adoption helped to fuel the company’s first profitable quarter, according to […]
Vericel CEO: Industry has reached ‘watershed moment’ for cell therapies
Shares in Cambridge-based Vericel Corp (NSDQ:VCEL) surged last year after the FDA approved its bioresorbable scaffold for cartilage repair. The product, Maci, is the first FDA-approved implant to use healthy cartilage tissue from a patient’s own knee to grow cells on the scaffold. Since the product’s approval in December 2016, surgeon uptake has helped to fuel the company’s continued […]
FDA approves first bioresorbable scaffold with autologous cells for cartilage repair
Vericel Corp (NSDQ:VCEL) shares soared 56% today after the Cambridge, Mass.-based company said the FDA approved its bioresorbable scaffold for cartilage repair. The product, Maci, is the 1st FDA-approved implant to use healthy cartilage tissue from a patient’s own knee to grow cells on the scaffold. “Different cartilage defects require different treatments, so therapy must be […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn